Genomic Tests
Comprehensive Genomic Profiling using Next-Generation Sequencing with Machine/deep Learning
Solid Tumors
Liquid Trace™:
Solid Tumor Profile- TAT
5-7 Days - Indications
Chromosomal abnormalities, gene amplifications, HRR, MRD, ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, PIK3CA, PTEN, EGFR amplification, AKT1, RAS
- - Sample Type
Peripheral blood - Sample Requirements
Peripheral blood: 8-10 ml.
EDTA tube preferred - Results Reported
DNA+RNA - Monitoring
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile Plus™- TAT
5-10 Days - Indications
ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping and various alternative splicing,
MET, HER2,
EGFR amplification,
PIK3CA, PTEN, AKT1, RAS and HRD
- - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile™ 434 Genes
- TAT
5-7 Days - Indications
All solid tumors:
Mutations in 434 genes,
copy number variation and chromosomal structural abnormalities,
TMB, MSI, HRD
- - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor Fusion / Expression Profile
1501 Genes
- TAT
7-10 Days - Indications
ALL Solid tumors:
Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 & other sarcoma genes
Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
ERBB2, MDM2
Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
Mutations in all 1400 genes - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Liquid Trace™:
Hematology Profile- TAT
5-7 Days - Indications
Chromosomal abnormalities, gene amplifications, multiple myeloma, lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, MDS, CMML, AML, MPN, lymphoma, MRD, VEXAS syndrome, HPV, EBV
- - Sample Type
Peripheral blood - Sample Requirements
Peripheral blood: 8-10 ml.
EDTA tube preferred
- - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile Plus™- TAT
5-10 Days - Indications
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia Includes IgVH mutation status
- - Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile™ 179 Genes
- TAT
5-7 Days - Indications
MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases, VEXAS
- - Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test